



Government of Pakistan
Ministry of National Health Services, Regulations & Coordination
Drug Regulatory Authority Of Pakistan
Health & OTC Products Division (Non-Drugs)

Islamabad, the 22nd August, 2021

“SAY NO TO CORRUPTION”

Subject: Submission of deficient information / documents

The applications of following applicants were placed before the Enlistment Evaluation Committee (EEC) in its 89th meeting held on 29th April, 2021 and the same have been deferred being deficient of the information / documents as specified in column (3) of the Table below which may be furnished within 20 days of uploading of this letter on official website of DRAP along with soft data as per **Annexed Format** at the end of this letter/document. Replies received after given time will not be entertained:-

S.No	Brand name	Decision
(1)	(2)	(3)
M/s Serena Laboratories, 16-17/C, Punjab Small Industrial Estate, Ferozpur Road, Kasur (E. No. 01094)		
1.	Serena Fast Move Cream	Deferred for change of Brand name
M/s. Dr. Zia Homoeopathic Pharma DZHP, (E.No. 00176) Plot No. 18, Sector - 14 Korangi Industrial Area, Karachi		
2.	Acidum carbolicum (Potencies) Acidum carbolicum 6x to CM (EHPI Specifications)	Deferred for submission of safety profile of carbolic acid preparation to oral use.
3.	Acidum fluoricum (Potencies) Acidum fluoricum 6x to CM (EHPI Specifications)	Deferred for submission of safety profile of acidum fluoricum preparation to oral use and its official monograph
4.	Acidum hydrocyanicum (Potencies) Acidum hydrocyanicum 6x to CM (EHPI Specifications)	Deferred for submission of safety profile of acidum Hydrocyanicum preparation to oral use and its official monograph
5.	Acidum lacticum (Potencies) Acidum lacticum 6x to CM (EHPI Specifications)	Deferred for submission of safety profile of acidum lacticum preparation to oral use and its official monograph
6.	Acidum muriaticum (Potencies) Acidum muriaticum 6x to CM (EHPI Specifications)	Deferred for submission of safety profile of acidum muriaticum preparation to oral use and its official monograph
7.	Acidum nitricum (Potencies) Acidum nitricum 6x to CM (EHPI Specifications)	Deferred for submission of safety profile of acidum nitricum preparation to oral use and its official monograph
8.	Acidum picricum (Potencies) Acidum picricum 6x to CM (EHPI Specifications)	Deferred for submission of safety profile of acidum picricum preparation to oral use and its official monograph
9.	Acidum sulphuricum (Potencies) Acidum sulphuricum 6x to CM (EHPI Specifications)	Deferred for submission of safety profile of acidum sulphuricum preparation to oral use and its official monograph
10.	Adrenalinum (Potencies) Adrenalinum 6x to CM (EHPI Specifications)	Deferred for submission of source of adrenalinum and evidence stating source of adrenalinum is not contaminated with TSE, E-coli and salmonella.
11.	Asterius rubens (Potencies) Asterius rubens 3x to CM (EHPI Specifications)	Deferred for submission of evidence stating source of Asterius rubens is not contaminated with TSE, E-coli and salmonella.

Shaukat

S.No	Brand name	Decision
(1)	(2)	(3)
12.	Carboneum sulphuratum (Potencies) Carboneum sulphuratum 3x to CM (EHPI Specifications)	Deferred for submission of safety profile of carbonium sulphuratum and its official monograph.
13.	Histaminum (Potencies) Histaminum 6x to CM (EHPI Specifications)	Deferred for submission of official monograph.
14.	Lac caninum (Potencies) Lac caninum 3x to CM (EHPI Specifications)	Deferred for submission of official monograph of lac caninum.
15.	Lac defloratum (Potencies) Lac defloratum 3x to CM (EHPI Specifications)	Deferred for submission of official monograph of lac defloratum.
16.	Lactuca virosa (Potencies) Lactuca virosa 3x to CM (EHPI Specifications)	Deferred for official monograph and safety profile of lactuca virosa.
17.	Mel cum sale (Potencies) Mel cum sale 3x to CM (EHPI Specifications)	Deferred for submission of official monograph of mel cum sale
18.	Moschus (Potencies) Moschus 6x to CM (EHPI Specifications)	Deferred for submission of official monograph of Moschus and evidence stating source of Moschus is not contaminated with TSE, E-coli and salmonella.
19.	Naphthalin (Potencies) Naphthalin 3x to CM (EHPI Specifications)	Deferred for submission of official monograph of naphthalin.
20.	Oleum jecoris aselli (Potencies) Oleum jecoris aselli 3x to CM (EHPI Specifications)	Deferred for evidence stating source of oleum jac is not contaminated with TSE, E-coli and salmonella.
21.	Pituitary gland (Potencies) Pituitary gland 6x to CM (EHPI Specifications)	Deferred for submission of source of pituitary gland and evidence stating source of pituitary gland is not contaminated with TSE, E-coli and salmonella.
22.	Platinum metallicum (Potencies) Platinum metallicum 6x to CM (EHPI Specifications)	Deferred for official monograph of platinum metallicum.
23.	Sepia (Potencies) Sepia 6x to CM (EHPI Specifications)	Deferred for evidence stating source of sepia is not contaminated with TSE, E-coli and salmonella.
24.	Testes (Potencies) Orchitinum 6x to CM (EHPI Specifications)	Deferred for submission of official monograph, source of orchitinum and evidence stating source of orchitinum is not contaminated with TSE, E-coli and salmonella.
25.	Acidum picricum Ø=3CH (Low potency Mother tincture) Acidum picricum 3CH (EHPI) (EHPI Specification)	Deferred for submission of safety profile and official monograph of acidum picricum.
26.	Carboneum sulphuratum Ø (Mother tincture) Carboneum sulphuratum(EHPI) (EHPI Specification)	Deferred for official monograph and safety profile of carbonium sulphuratum.
27.	Lactuca virosa Ø (Mother tincture) Lactuca virosa(EHPI) (EHPI Specification)	Deferred for official monograph and safety profile of lactuca virosa.
28.	Lobelia inflata Ø (Mother tincture) Lobelia inflata(EHPI) (EHPI Specification)	Deferred for safety profile of lobelia inflata.
29.	Rauwolfia serpentine Ø (Mother tincture) Rauwolfia serpentine(EHPI) (EHPI Specification)	Deferred for safety profile of rauwolfia serpentine mother tincture.
30.	Sarracenia purpurea Ø (Mother tincture) Sarracenia purpurea(EHPI) (EHPI Specification)	Deferred for official monograph of sarracenia purpurea.
31.	Strophanthus hispidus Ø (Mother tincture)	Deferred for safety profile of strophanthus hispidus mother tincture.

S.No	Brand name	Decision
(1)	(2)	(3)
	Strophanthus hispidus(EHPI) (EHPI Specification)	
M/s Pakistan Drug House (Pvt.) Ltd Plot No. F/244-B, S.I.T.E Karachi (E No. 01132)		
32.	RIO FERRUM TONIC	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> The applied formulation contains Nux Vomica Q which is a toxic plant preparation. However, the preparations of toxic plants below 6x cannot be prepared. Need revision of form-3 accordingly. Provide monographs of Lecithinum Ex Soya and Rubia Cordifolia.
33.	RIO APPETISER SYRUP	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> Provide monogprha of Quassia amara.
34.	RIO ALETRIS CORDIAL TONIC	EEC decided to defer the application for enlistment for the change of brand name.
35.	RIO GINSENG TONIC	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> Provide monograph of Siberian Ginseng and Chinese Astragalus Root.
M/s Diamond Unani Pharma, 73-JB Jhapal – Jhang Road, Faisalabad (E. No. 01178)		
36.	Diamond Roghan Badam	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> Provide evidence of availability of oil extraction equipment/facility. Provide manufacturing method of oil including extraction of oil from crude herbal ingredients at manufacturing site.
37.	Diamond Roghan Kalonji	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> Provide evidence of availability of oil extraction equipment/facility. Provide manufacturing method of oil including extraction of oil from crude herbal ingredients at manufacturing site.
38.	Diamond Roghan Narial	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> Provide evidence of availability of oil extraction equipment/facility. Provide manufacturing method of oil including extraction of oil from crude herbal ingredients at manufacturing site.
39.	Diamond Roghan Loung	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> Provide evidence of availability of oil extraction equipment/facility. Provide manufacturing method of oil including extraction of oil from crude herbal ingredients at manufacturing site.
40.	Diamond Roghan darchini	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> Provide evidence of availability of oil extraction equipment/facility. Provide manufacturing method of oil including extraction of oil from crude herbal ingredients at manufacturing site.
41.	Diamond Roghan Chambeli	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> Provide evidence of availability of oil extraction equipment/facility. Provide manufacturing method of oil including extraction of oil from crude herbal ingredients at manufacturing site.
42.	Diamond Roghan Kadu Each 10ml contains:	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> Provide evidence of availability of oil extraction equipment/facility. Provide manufacturing method of oil including extraction of oil from crude herbal ingredients at manufacturing site.
43.	Diamond Roghan Khashkhash	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> Provide evidence of availability of oil extraction equipment/facility.

S.No	Brand name	Decision
(1)	(2)	(3)
		<ul style="list-style-type: none"> • Provide manufacturing method of oil including extraction of oil from crude herbal ingredients at manufacturing site.
44.	Diamond Roghan Amla	<p>EEC decided to defer the application for enlistment due to following reasons:</p> <ul style="list-style-type: none"> • Provide evidence of availability of oil extraction equipment/facility. • Provide manufacturing method of oil including extraction of oil from crude herbal ingredients at manufacturing site.
45.	Diamond Olive Oil	<p>EEC decided to defer the application for enlistment due to following reasons:</p> <ul style="list-style-type: none"> • Provide evidence of availability of oil extraction equipment/facility. • Provide manufacturing method of oil including extraction of oil from crude herbal ingredients at manufacturing site.
46.	Diamond Roghan Castor Oil	<p>EEC decided to defer the application for enlistment due to following reasons:</p> <ul style="list-style-type: none"> • Provide evidence of availability of oil extraction equipment/facility. • Provide manufacturing method of oil including extraction of oil from crude herbal ingredients at manufacturing site.
47.	Diamond Roghan Mustard Oil	<p>EEC decided to defer the application for enlistment due to following reasons:</p> <ul style="list-style-type: none"> • Provide evidence of availability of oil extraction equipment/facility. • Provide manufacturing method of oil including extraction of oil from crude herbal ingredients at manufacturing site.
48.	Diamond Honey	<p>EEC decided to defer the application for enlistment due to following reasons:</p> <ul style="list-style-type: none"> • As per application for enlistment (Form-3), the firm is repacking the Honey. Justify the applied product as finished formulation w.r.t. manufacturing processes.
49.	Diamond Arq-Badian	<p>EEC decided to defer the application for enlistment due to following reasons:</p> <ul style="list-style-type: none"> • Form-3 needs to be revised w.r.t. mentioning the specification of each ingredient. • Provide all undertakings duly signed by the owner of the firm. • Provide monograph of ingredient. • Provide finished product testing method.
50.	Diamond Arq-Ajowan	<p>EEC decided to defer the application for enlistment due to following reasons:</p> <ul style="list-style-type: none"> • Form-3 needs to be revised w.r.t. mentioning the specification of each ingredient. • Mention name of ingredient as per monograph. • Provide all undertakings duly signed by the owner of the firm. • Provide monograph of ingredient. • Provide finished product testing method. • Revise the dose of Ajwain (Hyoscyamus Nigar) and provide safety undertaking regarding safety of applied formulation.
51.	Diamond Arq-Mako	<p>EEC decided to defer the application for enlistment due to following reasons:</p> <ul style="list-style-type: none"> • Form-3 needs to be revised w.r.t. mentioning the specification of each ingredient. • Provide all undertakings duly signed by the owner of the firm. • Provide monograph of ingredient. • Provide finished product testing method.
52.	Diamond Arq-Chuarqa	<p>EEC decided to defer the application for enlistment due to following reasons:</p> <ul style="list-style-type: none"> • Form-3 needs to be revised w.r.t. mentioning the specification of each ingredient. • Mention name of ingredient as per monograph. • Provide all undertakings duly signed by the owner of the firm. • Provide monograph of ingredient. • Provide finished product testing method.

S.No	Brand name	Decision
(1)	(2)	(3)
		<ul style="list-style-type: none"> • Revise the dose of Ajwain (Hyoscyamus Nigar) and provide safety undertaking regarding safety of applied formulation.
53.	Diamond Arq-Gulab	<p>EEC decided to defer the application for enlistment due to following reasons:</p> <ul style="list-style-type: none"> • Form-3 needs to be revised w.r.t. mentioning the specification of each ingredient. • Provide all undertakings duly signed by the owner of the firm. • Provide monograph of ingredient. • Provide finished product testing method.
54.	Diamond Arq-Kansi	<p>EEC decided to defer the application for enlistment due to following reasons:</p> <ul style="list-style-type: none"> • Form-3 needs to be revised w.r.t. mentioning the specification of each ingredient. • Provide all undertakings duly signed by the owner of the firm. • Provide monograph of ingredient. • Provide finished product testing method.
55.	Diamond Arq-Podina	<p>EEC decided to defer the application for enlistment due to following reasons:</p> <ul style="list-style-type: none"> • Form-3 needs to be revised w.r.t. mentioning the specification of each ingredient. • Mention name of ingredient as per monograph. • Provide all undertakings duly signed by the owner of the firm. • Provide monograph of ingredient. • Provide finished product testing method.
56.	Diamond Arq-Gaozaban	<p>EEC decided to defer the application for enlistment due to following reasons:</p> <ul style="list-style-type: none"> • Provide botanical scientific name of active ingredient. Apparently, the applied formulation comprised of toxic ingredient, need clarification.
57.	Diamond Arq-E-Shireen	<p>EEC decided to defer the application for enlistment due to following reasons:</p> <ul style="list-style-type: none"> • Form-3 needs to be revised w.r.t. mentioning the specification of each ingredient. • Provide all undertakings duly signed by the owner of the firm. • Provide monograph of ingredient. • Provide finished product testing method.
58.	Diamond Arq-e-Ifsinteen	<p>EEC decided to defer the application for enlistment due to following reasons:</p> <ul style="list-style-type: none"> • Form-3 needs to be revised w.r.t. mentioning the specification of each ingredient. • Provide all undertakings duly signed by the owner of the firm. • Provide monograph of ingredient. • Provide finished product testing method.
59.	Diamond Cough-Gyy Syrup	<p>EEC decided to defer the application for enlistment due to following reasons:</p> <ul style="list-style-type: none"> • Brand name needs to be changed. • Revise name of each ingredient as per monographs. • Provide all undertakings duly signed by the owner of the firm.
60.	Diamond Dee Gas Syrup	<p>EEC decided to defer the application for enlistment due to following reasons:</p> <ul style="list-style-type: none"> • Brand name needs to be changed. • Form-3 needs to be revised w.r.t. mentioning the specification of each ingredient. • Revise name of each ingredient as per monographs. • Provide all undertakings duly signed by the owner of the firm. • Provide monograph of all ingredients. • Provide finished product testing method.

**M/s Brooklyn Pharmaceuticals,
Plot No. B-1, Small Industries Estate, Taxila (E. No. 01181)**



S.No	Brand name	Decision
(1)	(2)	(3)
61.	Brooklyn's "OREH" Oral Powder (Sachet)	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> • The firm applied ORS formulation which is added in the list of common molecules.
M/s the Searle Company Limited (Searle Healthcare), F-319, S.I.T.E, Karachi (E. No. 01163)		
62.	Searle's Digigaz Capsules	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> • The applied formulation contains enzymes which are added in the list of common molecules. • Undertaking regarding submission of stability data is unsigned by the owner of the firm.
63.	Searle's Ostegemod Plus Capsules	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> • Provide monograph of Aminolock Collagen • Mention salt of each elemental ingredient on revised form-3 • Undertaking regarding submission of stability data is unsigned by the owner of the firm.
64.	Searle's Osteokal Capsules	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> • The applied formulation contains Glucosamine sulphate which is added in the list of common molecules. • Undertaking regarding submission of stability data is unsigned by the owner of the firm.
65.	Searle's Osteokal Plus Capsules	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> • The applied formulation contains Glucosamine Chondroitin complex sulphate which are added in the list of common molecules. • Form-3 needs to be revised w.r.t. mentioning the salt of each elemental ingredient. • Form-3 needs to be revised w.r.t. mentioning the strength of each active ingredient. • Form-3 needs to be revised w.r.t. mentioning the specification of each ingredient. • Undertaking regarding submission of stability data is unsigned by the owner of the firm.
M/s Havo Pharmaceuticals (Nutraceutical Division), Plot No. P-28 (A) Phase-IA M-3 Industrial Estate, Sahianwala Faisalabad. (E. No. 01180)		
66.	HAVO'S NOCID SACHET	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> • The firm applied duplicate formulation with brand name Healtan Sachet. • Brand name needs to be changed,
67.	HAVO'S HEALTON SACHET	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> • The firm applied duplicate formulation with brand name Nocid Sachet. • Brand name needs to be changed.
68.	HAVO'S FLU-NO Joshanda	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> • The applied formulation contains ephedra gerardiana and papaver somniferum which are controlled substances / precursor. • The firm is using herbs in crude form while possess nutraceutical facility.
69.	HAVO'S NOCID SYRUP	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> • Brand name needs to be changed. • The applied formulation contains sodium bicarbonate which is added in the list of common molecules.
70.	HAVO'S NEURO G SYRUP	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> • Brand name needs to be changed.

S.No	Brand name	Decision
(1)	(2)	(3)
		<ul style="list-style-type: none"> • Provide monographs of extracts of Bacopa monnieri and lavendulan angustifolia.
M/s Millat Laboratories (Pvt.) Ltd., Plot No.41-A/1, Industrial Estate, Hayatabad, Peshawar (E. NO. 01155)		
71.	Millat's DIA CURE HERBAL POWDER SACHET	EEC decided to defer the application for enlistment for the change of brand name.
72.	Millat's HAB E HAMAL AMBARI:	EEC decided to defer the application for enlistment for the change of brand name.
73.	Millat's HAB PACHIS ALAA	EEC decided to defer the application for enlistment for the change of brand name.
74.	Millat's HAB QABAZ KUSHAH	EEC decided to defer the application for enlistment for the change of brand name.
75.	Millat's HAB-E-MANSOREEN KHAS	EEC decided to defer the application for enlistment for the change of brand name.
76.	Millat's HAB-E-BAWASIR KHAS Tablet	EEC decided to defer the application for enlistment for the change of brand name.
77.	Millat's JARI NILL CAPSULE	EEC decided to defer the application for enlistment for the change of brand name.
78.	Millat's SPERM DOC CAPSULE	EEC decided to defer the application for enlistment for the change of brand name.
79.	Millat's LECONILL CAPSULE	EEC decided to defer the application for enlistment for the change of brand name.
80.	Millat's SCIATIN PLUS CAPSULE	EEC decided to defer the application for enlistment for the change of brand name.
81.	Millat's Arq E Khas Motapa Door	EEC decided to defer the application for enlistment for the change of brand name.
82.	Millat's GESTROMINT SYRUP	EEC decided to defer the application for enlistment for the change of brand name.
M/s Sharay Pharma Labs, Jalleke (Sarenky) Road, 1-Km Off Phool Nagar Bypass, 60-Km Road, Lahore (E No. 01177)		
83.	Sharay's SHECA CAPSULES	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> • Provide monograph of Calcified egg shell.
84.	Sharay's MULTIMALT SYRUP	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> • Provide monograph of Phyllanthus Urinaria.
85.	Sharay's MULTIMALT TABLET	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> • Provide monograph of Phyllanthus Urinaria.
86.	Sharay's SKIN ACE TABLET	Deferred for the change of brand name.
M/s Burj Health Care (E. No. 00369) 257 Sector-5, Korangi Industrial Area, Karachi		
87.	Burj's Arthro MAX Tablet	EEC decided to defer the application for enlistment due to following reasons: The applied formulation contains Glucosamine (as sulphate and Chondroitin Sulphate which are in the list of common molecules and defred till the finalization of policy decision
88.	Burj's BeYung max Tablet	EEC decided to defer the application for enlistment due to following reasons: Change of brand name
M/s. Bion Life Sciences (E. No. 00367) Lakhoki, off 4km Bandia Road, (1-E Alamdar Road, Near Ranger Head Quarter Al-Faisal Town) Lahore		
89.	Bion Life Sciences' Biowomen Capsule	EEC decided to give final opportunity for submission of alternative brand name
M/s Al-Ain Nutro, (E. No. 00503) 12-D/A, Ghazi Park, Peco Road, Kot Lakhpat Industrial Estate, Lahore-Pakistan (Nutraceutical)		
90.	AI-AIN NUTRO'S Ain Sleep Tablet	EEC decided to defer the application for enlistment due to following reasons: The applied formulation contains Melatonine which is in list of common molecule and deferred till the finilization of policy decision

Shudat

S.No (1)	Brand name (2)	Decision (3)
Wilshire Laboratories Pvt Ltd, Lahore Plot No.5, Farooq Industrial Estate, 20-KM, Ferozepur Road, Lahore		
91.	Fastrel Ointment	EEC decided to defer the application for enlistment due to following reasons: The applied formulation contains wintergreen oil which is in the list of common molecule and defred till the finalization of policy decision Change of brand name is required
92.	Beano (Brand Name Changed To Rytill) Tablet	EEC decided to defer the application for enlistment due to following reasons: The applied formulation contains Alpha-D galactosidase which is in the list of common molecule and defred till the finalization of policy decision
93.	Argin 1Gm Sachet	EEC decided to give final opportunity for submission of official Monograph of L-arginine L aspartate
M/S Nectar Pharmaceutical Nutritional Health Sciences (E.No. 01007) 2-km on East Shahalam Bridge, Charsadda Road, Peshawar		
94.	Nectar's Ivy Cough Syrup	EEC decided to give final opportunity for submission of alternative brand name
M/S SALBION HEALTH SCIENCES (PVT.) LTD 23-km, Sheikhpura Road, Lahore		
95.	Salbion's Asonate-D	EEC decided to defer the application for enlistment due to following reasons: The applied formulation contains Ossein mineral complex which is in the list of common molecule and deferred till the finalization of policy decision
96.	Salbion's Slimmy Sachet	EEC decided to give final opportunity for submission of alternative brand name
M/s. Royal Laboratories (00301) 22-24 Farooq Industrial Estate, 20 Km Ferozepur Road, Lahore		
97.	Novagain Capsules	EEC decided to give final opportunity for submission of alternative brand name
98.	Royal Laboratories' Acidin Syrup	EEC decided to defer the application for enlistment due to following reasons: The applied formulation contains Sodium bicarbonate which is in the list of common molecule and defred till the finalization of policy decision
M/s Greektec (Pvt) Ltd (Eno 0091) Plot No. D-30/A (First Floor), S.I.T.E,-II, Phase-I, Super Highway, Karachi		
99.	Ceebrox Tablet	EEC decided to give final opportunity for submission of alternative brand name
M/s Bio Classic Pharma (E. No. 00925) 43-C, Sunder Industrial Estate, Lahore		
100.	Bio Classic's Mom C Tablets	EEC decided to defer the application for enlistment due to following reasons: The applied formulation contains N- Acety cysteine which is in list of common molecule and defred till the finalization of policy decision
M/s Animal Life Care, (E. No. 00706) Opp. Zaman petrol Pump Multan Road, Bahawalpur-Pakistan [Veterinary: Homeopathic, Herbal/Unani]		
101.	Animal Life Care's Super Hit Powder	EEC decided to give final opportunity for submission of alternative brand name
M/s Izfaar Nutraceutical Industries Sun Lane 7th Km, Sundar Raiwind Road, Lahore-Pakistan		
102.	Coffnol Liquid	EEC decided to give final opportunity for submission of alternative brand name
103.	Diaranil Liquid	EEC decided to give final opportunity for submission of alternative brand name
104.	Cranfar UT Sachet	EEC decided to give final opportunity for submission of alternative brand name
105.	Folaad Liquid	EEC decided to defer the application for enlistment due to following reasons: The applied formulation contains Iron Polymaltose which is in list of common molecule and defred till the finalization of policy decision

S.No	Brand name	Decision
(1)	(2)	(3)
106.	Hivit Liquid	EEC decided to give final opportunity for submission of alternative brand name
107.	Fortamin Liquid	EEC decided to give final opportunity for submission of alternative brand name
108.	Cranfar UT Capsule	EEC decided to give final opportunity for submission of alternative brand name
109.	M. Vit Liquid	EEC decided to give final opportunity for submission of alternative brand name
M/s Bristol Mayer Biotech Pakistan, (E. No. 00973) 73-B Guldasht Town, Zarrar Shaheed Road, Lahore Cantt, Lahore		
110.	Bristol Mayer Biotech's Agilcart sachet	EEC decided to defer the application for enlistment due to following reasons: The applied formulation contains chondroitin sulphate and Glucosamine which are in the list of common molecule and deferred till the finalization of policy decision
111.	Bristol Mayer Biotech's Agilcart fort sachet	EEC decided to defer the application for enlistment due to following reasons: The applied formulation contains chondroitin sulphate and Glucosamine which are in the list of common molecule and deferred till the finalization of policy decision
M/s Innova Life Sciences (E.No.00) (Evaluator Sadaf Ahmad, AD-I)		
112.	Innova's Baromax Sachet	EEC decided to give final opportunity for submission of alternative brand name
113.	Innova's Glutarise Capsule	EEC decided to give final opportunity for submission of alternative brand name
114.	Innova's Sipsoda Sachet	EEC decided to defer the application for enlistment due to following reason: The applied formulation contains ingredient which is in list of common molecule and defer till the finalization of policy decision
115.	Innova's Depile Ointment	EEC decided to give final opportunity for submission of alternative brand name
116.	Innova's Orthorub Cream	EEC decided to defer the application for enlistment due to following reason: The applied formulation contains winter green oilingredient which is in list of common molecule and defer till the finalization of policy decision
117.	Innova's Lactif Drops	EEC decided to give final opportunity for submission of alternative brand name
118.	Innova's H-Mag Tablet	EEC decided to give final opportunity for submission of alternative brand name
119.	Innova's Biofolic Plus Tablet	EEC decided to give final opportunity for submission of alternative brand name


(Ayyaz Ahmad)

Secretary, Enlistment Evaluation Committee

ANNEXURE

The firm is directed to submit soft data in both MS Excel & MS Word on following formats in **USB ONLY.**

MS Excel Format

Sr. No.	Company name	Product Name	Dosage Form	Composition	Common name	Recommended use	Pack Size	Date of R&I submission
1.	(Company name, City) Without address	XYZ	Tablet	Each tablet contains: Abc (USP)...50mg	XXX	XXX	10's 20's	DD.MM.YYYY
2.								

MS Word Format

Sr. No.	Company name	Product Name and composition	Common name	Recommended use	Pack Size
1.	(Company name, City) Without address	XYZ Tablet Each tablet contains: Abc (USP)...50mg	XXX	XXX	10's 20's
2.					